Loading…
Medical Foods and Formulas Access Act of 2025
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,674 other S bills in the 119th — cohort avg 32d
Medical Foods and Formulas Access Act of 2025 This bill expands coverage under Medicare, Medicaid, the Children’s Health Insurance Program (CHIP), and the Federal Employees Health Benefits Program to include medically necessary food and associated equipment and supplies. The bill defines medically necessary food as specially formulated and processed products (e.g., nutritional formulas) prescribed by health care practitioners for individuals who have special dietary requirements because of certain digestive or metabolic disorders or conditions.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2026 · third_quarter · Health Issues
FY 2027 federal funding for DoD peer-reviewed medical research and the National Institutes of Health; Improvements in FDA rare disease New Drug Application review process; H.R. 5684 / S. 3304 - Medical Foods and Formulas Access Act.
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
FY 2027 Funding for medical research at the NIH and CDC FY 2027 Appropriations - DoD Congressionally Directed Medical Research Program S 864/ HR 6423 Help Ensure Lower Patient Copays Act S 526 Pharmacy Benefit Manager Transparency Act HR 5509/ S 2903: Safe Step Act S 3304 / HR 5684 Medical Foods and Formula Access Act CMS - Interoperability Standards and Prior Authorization for Drugs proposed rule CMS - RFI on step therapy in Medicare CMS - Reimbursement for infused biosimilars CMS - Medicare Competitive bidding for ostomy supplies CMS - Medicaid work requirements FDA - Approvals for pediatric IBD medications HHS - FY 2027 NBPP OMB - Proposed rule on Federal grantmaking
Client expense: $40,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2026 · second_quarter · Health Issues
Support the Medical Foods and Formulas Access Act (H.R. 5684, S.3304) Support the Prior Authorization Reform for Autoimmune and Blood Disorders Act (H.R. 9192) which applies to ERISA / self-funded plans. Requires health plans to honor prior authorization for autoimmune and blood disorder treatments for a 12-month period.
Client expense: Not reported · Firm income: $25,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
FY 2027 federal funding for DoD peer-reviewed medical research and the National Institutes of Health; Improvements in FDA rare disease New Drug Application review process; H.R. 5684 / S. 3304 - Medical Foods and Formulas Access Act.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
FY 2027 Funding for medical research at the NIH and CDC FY 2027 Appropriations - DoD Congressionally Directed Medical Research Program S 864/ HR 6423 Help Ensure Lower Patient Copays Act S 526 Pharmacy Benefit Manager Transparency Act HR 5509/ S 2903: Safe Step Act S 3304 / HR 5684 Medical Foods and Formula Access Act CMS - Interoperability Standards and Prior Authorization for Drugs proposed rule CMS - RFI on step therapy in Medicare CMS - Reimbursement for infused biosimilars CMS - Medicare Competitive bidding for ostomy supplies FDA - Approvals for pediatric IBD medications HHS - FY 2027 NBPP
Client expense: $40,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2026 · first_quarter · Health Issues
Support the Medical Foods and Formulas Access Act (H.R. 5684, S.3304) Pediatric indications for biologic products to treat inflammatory bowel disease
Client expense: Not reported · Firm income: $25,500
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
Advocacy on health care issues relating to genetics and genetic testing, including H.R.4709, the Newborn Screening Saves Lives Reauthorization Act of 2025; H.R. 6208, Access to Genetic Counselor Services Act; H.R. 5684/S 3304, Medical Foods and Formulas Access Act; H.R. 7118, Genomic Answers for Childrens Health Act; and H.R. 2471, Right Dose Right Now Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
FY 2027 federal funding for DoD peer-reviewed medical research and the National Institutes of Health; Improvements in FDA rare disease New Drug Application review process; H.R. 5684 / S. 3304 - Medical Foods and Formulas Access Act.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Health Issues
Support the Medical Foods and Formulas Access Act (H.R. 5684, S.3304) Support the Cure Hepatitis C Act (S. 1941) Pediatric indications for biologic products to treat inflammatory bowel disease
Client expense: Not reported · Firm income: $25,500
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Health Issues
Advocacy on health care issues relating to genetics and genetic testing, including funding and authorization for the Newborn Screening program, H.R.4709, the Newborn Screening Saves Lives Reauthorization Act of 2025, as well as H.R. 6208, Access to Genetic Counselor Services Act, and J/R/5684/S3304, Medical Foods and Formulas Access Act.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| GA |
| Raphael G. Warnock | Democratic | GA |
| Sheldon Whitehouse | Democratic | RI |